Literature DB >> 1708182

[Sudeck disease].

A Enderle1, A Gregl.   

Abstract

In 1900, the Hamburg surgeon P.H.M. Sudeck was the first to describe the clinical and radiological symptomatology of the disorder to which he later lent his name. He devoted his scientific career to this disorder, "acute inflammatory atrophy" of bone and soft-tissue as he called it. He elaborated the histology of the disorder with his students and advocated the pathogenic peripheral humoral theory. In later years seven further attempts to explain the pathogenesis were published. The present paper notes that this disorder, which can be divided into three distinct stages, is diagnosed mainly on the basis of clinical factors, above all in the early stage, and that x-rays in the early stages are difficult to differentiate from those of immobilisation osteoporosis since both disorders can manifest as patchy rare fraction and fibrous osteolysis in subchondral bone and old growth plates. Moreover, the author also notes that 10% of all Sudeck cases are not preceded by trauma; these must be understood as spontaneous Sudeck or as Sudeck after distant disturbances. A few sources also refer to Sudeck's dystrophy in the presence of lymphatic congestion. Another, special form of Sudeck's atrophy, is the shoulder-hand syndrome which, however, cannot always be differentiated precisely from rheumatic disorders or dystrophic contractures.

Entities:  

Mesh:

Year:  1990        PMID: 1708182

Source DB:  PubMed          Journal:  Z Lymphol        ISSN: 0343-8554


  2 in total

1.  Glomus Tumor of the Lower Extremity Previously Misdiagnosed as Complex Regional Pain Syndrome in Close Proximity to a Myxofibrosarcoma: A Case Report.

Authors:  Alireza K Nazemi; John Grossi; Felix B Tavernier; Brendan F Boyce; David E Komatsu; Fazel A Khan
Journal:  J Am Acad Orthop Surg Glob Res Rev       Date:  2022-07-06

2.  Flexion contractures associated with a malignant neoplasm: 'A paraneoplastic syndrome?'.

Authors:  E M Eekhoff; P A van der Lubbe; F C Breedveld
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.